October 4, 2018 — Pulmonary artery denervation (PADN) is associated with significant improvements in hemodynamic and...
Hypertension
This page includes news and new technology on hypertension. The condition is caused by abnormally high blood pressure that causes excess force and pressure of the blood against the artery walls. Long-term, this can cause damage the vessels and contributes to heart disease. Therapies include antihypertensive medications such as diuretics and renal denervation therapy.
A series of procedural images of a pulmonary artery denervation for CpcPH from the PADN-5 trial.
News | Hypertension | October 04, 2018
News | Hypertension | October 02, 2018
October 2, 2018 — Two-year results of the Moderato I Study demonstrated immediate, substantial and sustained...
News | Pharmaceuticals | August 27, 2018
August 27, 2018 — Blood pressure and cholesterol-lowering...
News | Cardiac Diagnostics | August 03, 2018
August 3, 2018 — Even as a young adult, being overweight may cause...
News | Hypertension | July 30, 2018
July 30, 2018 — Approximately 75 percent of black and men women are...
News | Hypertension | July 05, 2018
July 5, 2018 — Physician practices now have access to new resources to improve their standard of quality care for...
News | Mobile Devices | June 13, 2018
June 13, 2018 — Medication management platform Medisafe released data showing that, on average,...
News | Renal Denervation | May 30, 2018
May 31, 2018 – ReCor Medical announced that the RADIANCE-HTN SOLO...
An example of renal denervation therapy being delivered. A catheter is inserted into the renal artery to ablate the nerves in the vessel wall that regulate vasoconstriction. This leaves the vessel permanently in the widest open position to allow greater blood flow to the kidneys.
Feature | Renal Denervation | May 30, 2018
May 30, 2018 — Despite the best efforts of clinicians to manage hypertension, it continues to increase and is now...
News | Renal Denervation | May 23, 2018
May 23, 2018 – At the 2018 EuroPCR Annual Meeting in Paris, Medtronic announced first-ever-data from the SPYRAL HTN-...
News | Renal Denervation | April 16, 2018
April 16, 2018 — Medtronic plc announced U.S. Food and Drug Administration (FDA) approval to begin an...
News | Hypertension | April 05, 2018
April 5, 2018 — YMCA of the USA (Y-USA) and the American Heart Association (AHA) are combining efforts to help more...
A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.
Feature | ACC | March 27, 2018 | Dave Fornell
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American...
